BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Hemophilia clinical trials and catalysts

Active industry-sponsored trials on ClinicalTrials.gov for hemophilia: 90 (29 sponsors; 13 newly posted in the last 180 days, 7 stopped in the last 180 days; 3 new-entrant sponsors). Momentum score 27.2, rank 7 of 91 on the disease-area ranking. As of 2026-11-18.

Phase distribution: Early Phase 1 0, Phase 1 5, Phase 2 11, Phase 3 37, Phase 4 7, N/A 30.

Most active sponsors, by phase

SponsorActive trialsBy phaseNew (window)Upcoming readouts
Pfizer PFE9NA 2, P3 6, P1 121
Novo Nordisk A/S NVO14NA 8, P3 5, P1 123
Hoffmann-La Roche7P3 4, P2 2, P4 111
Suzhou Alphamab Co., Ltd.4P3 3, P2 100
Hangzhou Gensciences Biopharmaceutical Co., Ltd.3P3 323
Sanofi SNY7P4 2, NA 3, P3 211
CSL Behring5P3 2, NA 300
Shanghai Xinzhi BioMed Co., Ltd.2P3 200
Biocad3P2 2, P3 101
Swedish Orphan Biovitrum3P4 2, P3 101
BioMarin Pharmaceutical BMRN2NA 1, P3 100
Gritgen Therapeutics Co., Ltd.2P2 1, P3 101
Shanghai RAAS Blood Products Co., Ltd. new entrant2P3 1, P2 121
Sinocelltech Ltd.2P3 1, P1 110
Bioverativ, a Sanofi company1P3 101
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.1P3 100
Jiangsu BioJeTay Biotechnology Co., Ltd.1P3 100
SK Plasma Co., Ltd.1P3 100
Bayer6NA 603
Octapharma3NA 1, P4 202
Baxalta now part of Shire2NA 1, P2 100
Regeneron Pharmaceuticals REGN2P2 1, NA 101
Takeda TAK2NA 200
Arditus Pte Ltd new entrant1P2 111
AryoGen Pharmed Co. new entrant1NA 111

New-entrant sponsors: Shanghai RAAS Blood Products Co., Ltd., Arditus Pte Ltd, AryoGen Pharmed Co..

Recently stopped trials

Upcoming trial readouts (next 90 days)

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-30 est.P3Gritgen Therapeutics Co., Ltd.NCT06833983 To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia AHemophilia Arecruiting50
2026-12-31 est.P3Hangzhou Gensciences Biopharmaceutical Co., Ltd.NCT06136507 Study of Efficacy and Safety of FRSW107 in Pediatric Patients With Severe Hemophilia ASevere Hemophilia Anot yet recruiting76
2026-12-31 est.P1/P2Shanghai RAAS Blood Products Co., Ltd.NCT07644832 An Open-label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic/Pharmacodynamic (PK/PD) CharacteristicsHemophilia A; Hemophilia B; Factor VII Deficiencyrecruiting76
2027-01-15 est.P3Bioverativ, a Sanofi companyNCT04644575 Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia AHemophilia Aactive not recruiting261
2027-02 est.P3Hangzhou Gensciences Biopharmaceutical Co., Ltd.NCT07663903 Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) On-Demand TreatmentSevere Hemophilia Aactive not recruiting60

Readouts in the last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-10-15 est.P3Suzhou Alphamab Co., Ltd.NCT06569108 Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B Without InhibitorsHemophilia A Without Inhibitor; Hemophilia B Without Inhibitoractive not recruiting125
2026-09-23P3CSL BehringNCT06738485 Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII ProductsCongenital Hemophilia Acompleted62
2026-09-15P1/P2BayerNCT03588299 Study to Test the Safety and How Well Patients With Severe Hemophilia A Respond to Treatment With BAY 2599023 (DTX 201), a Drug Therapy That Delivers a Healthy Hemophilia Acompleted11
2026-09-14P3Genzyme, a Sanofi CompanyNCT03754790 Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IXHemophiliacompleted281
2026-09-02 est.P2Suzhou Alphamab Co., Ltd.NCT06747416 KN057 Multiple Dose Study in Patients with Hemophilia a or Hemophilia B with or Without InhibitorsHemophilia a and Bnot yet recruiting24
2026-09 est.P3Jiangsu BioJeTay Biotechnology Co., Ltd.NCT06922045 Phase III Clinical Trial of STSP-0601 for Injection in Hemophilia PatientsHemophiliaactive not recruiting40
2026-08-04P2/P3Genzyme, a Sanofi CompanyNCT03974113 Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or BHemophiliacompleted32
2026-07-31 est.P3SK Plasma Co., Ltd.NCT06738901 An Open-label Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of SKP-0141 for the Treatment and Prophylaxis in Severe Hemophilia a PHemophilia A, Severenot yet recruiting55
2026-07-23P2Pfizer PFENCT03307980 Long-term Safety and Efficacy Study and Dose-Escalation Substudy of PF 06838435 in Individuals With Hemophilia BHemophilia Bterminated21
2026-07-07P3CSL BehringNCT06399289 Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Chinese Subjects With Hemophilia B Previously Treated With FIX TherapyHemophilia Bcompleted23
2026-07 est.P3Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.NCT06297655 A Clinical Study of Recombinant Human Coagulation Factor VIII for Injection in Patients With Severe Hemophilia AHemophilia Aactive not recruiting60
2026-06-02P3Swedish Orphan BiovitrumNCT05817812 A Study Evaluating Physical Activity and Joint Health in Severe Haemophilia A Patients ≥12 Years Treated Once Weekly With Efanesoctocog AlfaHemophilia A, Severecompleted93
2026-05-29P1/P2Be BiopharmaNCT06611436 BeCoMe-9: A Clinical Study of BE-101 for the Treatment of Adults With Moderately Severe or Severe Hemophilia BHemophilia B; Hemophilia B, Moderately Severe or Severeterminated5

Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "hemophilia"); readouts matched by condition text. Registry counts only; not a forecast.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.